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Letters to the Editormeta-analyses1,2 included nonrandom-
ized observational studies, data of
unadjusted crude mortality were
abstracted and combined. In contrast,
our preliminary meta-analysis3 of
adjusted risk estimates from non-
randomized studies have suggested
that DES use may increase mortality
at 1 year or more relative to CABG
for MVD. To assess whether DES
treatment for MVD increases follow-
up mortality relative to CABG, we up-
dated our previous meta-analysis,3
combining not unadjusted but adjusted
risk estimates.
Studies considered for inclusionmet
the following criteria: the design was
a comparative study (randomized con-
trolled trial or nonrandomized obser-
vational study); the study population
was limited to patients with MVD; pa-
tients were assigned to DES or CABG
treatment; and main outcomes in-
cluded adjusted (in case of observa-
tional studies) hazard ratios (HRs), or
odds ratios if HRs were unavailable,
for all-cause mortality at 1 year and
beyond. Our comprehensive search
(current through January 2011) identi-
fied 2 randomized trials4,5 and 11
nonrandomized studies. We included
2 randomized trials (Coronary Artery
Revascularization in Diabetes trial
[CARDia]4 and Synergy between Per-
cutaneous Coronary Intervention with
Taxus and Cardiac Surgery trial [SYN-
TAX ]5), although they included com-
plex single-vessel disease (6.9%) and
left main coronary artery disease with-
out MVD (12.7%), respectively. We
abstracted 2 unadjusted HRs from ran-
domized trials and 18 adjusted HRs
and 1 adjusted odds ratio from non-
randomized studies. Pooled analysis
of all the 21 risk estimates demon-
strated a statistically significant 24%
increment in mortality with DES
treatment relative to CABG in a ran-
dom-effects model (HR, 1.24; 95%
confidence interval, 1.02–1.50; P ¼
.03; Figure 1). There was significant
between-study heterogeneity (P ¼
.003) but little difference in the pooled
result from fixed-effects modeling242 The Journal of Thoracic and C(HR, 1.25; 95% confidence interval,
1.12–1.39; P< .0001). When 7 HRs
in double-vessel disease and 8 HRs in
triple-vessel diseasewere pooled sepa-
rately, DES treatment was associated
with, respectively, a statistically non-
significant 27% and a 36% increment
in mortality relative to CABG. Elimi-
nating the 2 randomized trials4,5 that
included a few with single-vessel
disease or left main coronary artery
disease without MVD did not substan-
tially change the pooled point estimate
(random-effects HR, 1.25; 95% confi-
dence interval, 1.005–1.55; P ¼ .045).
There was no evidence of significant
publication bias (P ¼ .88 by an
adjusted rank-correlation test, P ¼ .96
by a linear regression test).
Despite the results of the previous
unadjusted meta-analyses, including
that of Yan and collaborators,1,2 we
found our current adjusted meta-
analysis of mainly nonrandomized
observational studies with a few ran-
domized controlled trials to indicate
that DES treatment for MVD may in-
crease all-cause mortality at 1 year
and beyond by 24% relative to
CABG. CABG rather than DES treat-
ment should therefore be considered
for MVD, because follow-up mortal-
ity reduction must imply the greatest
clinical benefit among patients with
MVD. To cut the Gordian knot of
DES versus CABG for MVD, how-
ever, additional randomized trials are
needed.
Hisato Takagi, MD, PhD
Hideaki Manabe, MD
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We congratulate Takagi and col-
leagues on their updated meta-
analysis comparing drug-eluting stent
(DES) treatment with coronary artery
bypass grafting (CABG) for patients
with multivessel coronary artery dis-
ease. Our meta-analysis of trials
(1 randomized, 24 nonrandomized)
comparing CABGwith DES treatment
for multivessel coronary artery disease
showed similar rates of all-cause mor-
tality in the 2 groups but a lower inci-
dence of major adverse cardiac and
cerebrovascular events in the CABG
group at 1 year and beyond.1 Themajor
contributor to the increased incidence
of major adverse cardiac and cerebro-
vascular events seen in the DES group
was the increased rate of repeat revas-
cularization in that group.
Unlike our meta-analysis, in which
unadjusted hazard ratios from the ob-
servational studies were used, Takagi
and colleagues’ analysis used adjusted
hazard ratios to demonstrate signifi-
cantly increased mortality in the
DES group beyond 1 year. When trials
including patients with 2-vessel dis-
ease and 3-vessel disease were pooled
separately, no significant difference in
mortality was seen.
These studies provide further evi-
dence that CABG remains the stan-
dard of care for patients with
multivessel coronary artery disease.
In the 3-year outcomes of the Synergy
Letters to the Editorbetween Percutaneous Coronary In-
tervention with Taxus and Cardiac
Surgery (SYNTAX) trial, presented
at the 2010 European Association of
Cardio-Thoracic Surgery meeting,2
the incidence of major adverse cardiac
and cerebrovascular events remained
significantly greater among patients
undergoing percutaneous coronary in-
tervention than among those undergo-
ing CABG. This was a result of
greater rates of both repeat revascular-
ization and myocardial infarction be-
yond 1 year in the former group.
Improvements in surgical revascular-
ization are often overlooked. The main
criticism of surgery in the SYNTAX
trial (also shown in our meta-analysis)
is the increased rate of perioperative
strokecomparedwithpercutaneous cor-
onary intervention with DESs.1,3 There
has been renewed interest in off-pump
CABG, ideally without manipulation
of the ascending aorta, in an attempt to
decrease the rateofperioperative stroke.
We have recently published a meta-
analysis comparing off-pump CABG
with percutaneous coronary interven-
tion 4 The results suggest equivalent
rates of stroke for off-pump CABG
and percutaneous coronary intervention
(unlike the SYNTAXresults) but signif-
icantly lower rates of major adverse
cardiac and cerebrovascular events in
the surgical group. Debate surrounding
the relative graft patencies of conven-
tional CABG and off-pump CABG is
ongoing. There is evidence, however,
that when performed by surgeons expe-
rienced in the technically demanding
technique, off-pump CABG achieves
a graft patency equivalent to that of
CABG.5,6
The debate regarding CABG versus
DES treatment is complex, and the
goalposts are continually being
shifted by evolving DES technology.
This makes comparison of DES treat-
ment with CABG difficult—perhaps
indeed a Gordian knot in the question
of myocardial revascularization. A so-
lution, however, may not require the
resurrection of Alexander the Great
to cut the knot. Rather, well-The Journalconstructed trials (such as SYNTAX)
and then a combined approach to deci-
sion making involving both cardiolo-
gists and surgeons will ensure
selection of the most appropriate in-
tervention for each patient and ulti-
mately the best outcome.
J. James B. Edelman, MBBS
Tristan D. Yan, BSc, MBBS, PhD
Michael P. Vallely, MBBS, PhD
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MODEL ON A PERSONAL
COMPUTER
To the Editor:
We read the article by Solomon
and associates,1 ‘‘Simulating video-of Thoracic and Cardiovascular Surgeassisted thoracoscopic lobectomy: A
virtual reality cognitive task simula-
tion,’’ with great interest. We agree
with their virtual reality cognitive
task simulation and think what they
are doing is fantastic.
Video-assisted thoracic surgery
has replaced open thoracotomy in the
surgical treatment of many pleuropul-
monary diseases.2 Video-assisted tho-
racic surgery lobectomy has been
gaining in popularity for early-stage
lung cancer. On the other hand, ana-
tomic variations of the pulmonary
vessels present a potential risk of un-
controllable intraoperative bleeding;
thus, it is necessary to collect infor-
mation on the branching patterns of
pulmonary vessels preoperatively.3
We previously described the virtual
3-dimensional pulmonary model on
a personal computer (PC) for the pre-
operative simulation of video-assisted
thoracoscopic lung resection.4,5 Our
simulator has patient-specific anat-
omy incorporated.
In July 2001, we began using a vir-
tual 3-dimensional pulmonary model
on a PC in video-assisted thoraco-
scopic lung resection. A total of 140
patients underwent lobectomy and
158 patients underwent segmentec-
tomy or subsegmentectomy for lung
tumor.
By using 60 2-mm (at present 120
1-mm) high-resolution computed to-
mography images of the tumor and
hilum, in DICOM format, we could
mark on the pulmonary arteries, veins,
bronchi, and tumor. We attempted to
reconstruct these with anatomically
correct images using a freeware pro-
gram (CTTRY). After the images
were uploaded to a PC, the pulmonary
arteries, veins, and bronchi were
traced in the images. The location
and thickness of the bronchi and pul-
monary vasculature were rendered as
different-sized cylinders (Figure 1,
A). Next, on the basis of the resulting
numeric data, a 3-dimensional image
(Figure 1, B) was reconstructed using
shareware (Metasequoia). The recon-
structed images can be manipulatedry c Volume 142, Number 1 243
